Millennium Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Millennium Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.9M	Buy	43,000 +20,600	+92%	+$6.21M	﹤0.01%	2031
2026 Q1	$7.41M	Buy	22,400 +13,000	+138%	+$4.42M	﹤0.01%	2497
2025 Q4	$3.74M	Sell	9,400 -26,100	-74%	-$11.6M	﹤0.01%	3332
2025 Q3	$16.2M	Sell	35,500 -9,600	-21%	-$3.91M	0.01%	1907
2025 Q2	$14.7M	Sell	45,100 -15,300	-25%	-$4.23M	0.01%	1878
2025 Q1	$16.3M	Buy	60,400 +59,000	+4,214%	+$15.2M	0.01%	1725
2024 Q4	$329K	Sell	1,400 -6,100	-81%	-$1.6M	﹤0.01%	5020
2024 Q3	$2.06M	Buy	+7,500	New	+$1.95M	﹤0.01%	3676
2024 Q2	–	Sell	-2,300	Closed	-$344K	–	5831
2024 Q1	$344K	Sell	2,300 -3,800	-62%	-$634K	﹤0.01%	5049
2023 Q4	$1.17M	Sell	6,100 -18,200	-75%	-$3.1M	﹤0.01%	4033
2023 Q3	$4.3M	Sell	24,300 -20,900	-46%	-$3.99M	﹤0.01%	2831
2023 Q2	$8.59M	Buy	+45,200	New	+$8.96M	﹤0.01%	2165
2023 Q1	–	Sell	-17,900	Closed	-$4.25M	–	6314
2022 Q4	$4.25M	Buy	+17,900	New	+$3.82M	﹤0.01%	2954
2022 Q3	–	Sell	-50,800	Closed	-$7.41M	–	7027
2022 Q2	$7.41M	Buy	+50,800	New	+$7.21M	﹤0.01%	2376
2022 Q1	–	Sell	-51,000	Closed	-$8.65M	–	6850
2021 Q4	$8.65M	Sell	51,000 -14,000	-22%	-$2.6M	﹤0.01%	2305
2021 Q3	$12.3M	Sell	65,000 -35,000	-35%	-$6.57M	0.01%	1806
2021 Q2	$17M	Buy	100,000 +50,000	+100%	+$7.32M	0.01%	1355
2021 Q1	$7.06M	Buy	50,000 +15,000	+43%	+$2.26M	0.01%	2182
2020 Q4	$4.55M	Sell	35,000 -70,000	-67%	-$9.35M	﹤0.01%	2541
2020 Q3	$15.3M	Buy	+105,000	New	+$14.9M	0.02%	952
2013 Q3	–	Sell	-20,400	Closed	-$632K	–	3270
2013 Q2	$632K	Buy	+20,400	New	+$543K	﹤0.01%	2217

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management's ALNY Position: Q2 2026 in Review

Millennium Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 29% in Q2 2026, selling an estimated $39.8M and leaving 316,001 shares worth $95.1M. The position accounts for 0.03% of the portfolio, ranked #533.

Millennium Management first reported a position in ALNY in Q3 2013 and has held it in 43 quarters since. The position peaked at $251M in Q3 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Millennium Management held 316,001 shares of Alnylam Pharmaceuticals worth $95.1M as of Q2 2026.
Millennium Management sold 131,886 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $39.8M.
Alnylam Pharmaceuticals made up 0.03% of Millennium Management's portfolio in Q2 2026, its #533 holding.
Millennium Management first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 43 quarters since.
Millennium Management's Alnylam Pharmaceuticals position peaked at $251M in Q3 2025.
791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.